Cabenuva
Payments companies reported to CMS as associated with Cabenuva. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Cabenuva, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Cabenuva
These are the largest totals companies reported as associated with Cabenuva. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Wilfredo Cuevas | San Lorenzo, PR | General Practice | $221,478.60 |
| Douglas Cunningham | Phoenix, AZ | Family Medicine | $201,855.54 |
| Jay Gladstein | Los Angeles, CA | Infectious Disease | $167,591.95 |
| Matthew Herrmann | Los Angeles, CA | Internal Medicine | $145,975.13 |
| Zandraetta Tims-Cook | Atlanta, GA | Infectious Disease | $133,909.62 |
| Christopher Bettacchi | Marion, VA | Infectious Disease | $133,189.69 |
| Jesi Ramone | Brooklyn, NY | Internal Medicine | $132,160.82 |
| Julio Baco | Mayaguez, PR | General Practice | $124,241.42 |
| Gary Sinclair | Dallas, TX | Internal Medicine | $117,671.73 |
| Marc Tribble | Dallas, TX | Internal Medicine | $113,941.32 |
Prescribed Cabenuva?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.